20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
NECTAR 2021
The Network for European CNS Transplantation and Restoration (NECTAR) was founded over 25 years ago. Here, Dr Simon Stott presents a brief update on the events at NECTAR 2021.
Post-hoc analyses of the isradipine and nilotinib trial results
Results from major Parkinson’s clinical trials, of the blood pressure medication isradipine and the cancer treatment nilotinib, found that these drugs had no effect on the progression of the disease. Now, post-hoc analyses of the trial data have identified some interesting results that may deserve…
Farnesol: from perfume to Parkinson’s
A ground-breaking Cure Parkinson’s supported study that involved screening over 230,000 molecules has identified farnesol, a commonly found aromatic oil, as a new potential treatment of Parkinson’s.
Is Inhibikase ‘Abl’ to beat nilotinib in treating Parkinson’s?
Inhibikase Therapeutics has designed a novel drug that is similar to the drug nilotinib – previously tested in people with Parkinson’s – but is better at reaching its target in the brain.
Cure Parkinson’s launches legacy campaign
On 27 October, 50 long-time supporters of Cure Parkinson’s gathered at Micklefield Hall in Sarratt, Hertfordshire for the launch of our legacy campaign, Planting for a Cure.